Cássia Righy

Cássia Righy

Auto-generated profile, based on publicly available information

Cássia Righy

Department of Neurointensive Care, Instituto Estadual do Cerebro Paulo Niemeyer, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil (C.R.).

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2014 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
LDLuiz Gustavo Dubois
Luiz Gustavo Dubois
LCLoraine Campanati
Loraine Campanati
CRCassia Righy
Cassia Righy
IDIsabella D’Andrea-Meira
Isabella D’Andrea-Meira
TSTania Cristina Leite de Sampaio e Spohr
Tania Cristina Leite de Sampaio e Spohr
VNVivaldo Neto
Vivaldo Neto
Astrocytes, members of the glial family, interact through the exchange of soluble factors or by directly contacting neurons and other brain cells, such as microglia and endothelial cells. Astrocytic projections interact with vessels and act as additional elements of the Blood Brain Barrier (BBB). By mechanisms not fully understood, astrocytes can undergo oncogenic transformation and give rise to gliomas. The tumors take advantage of the BBB to ensure survival and continuous growth. A glioma can develop into a very aggressive tumor, the glioblastoma (GBM), characterized by a highly heterogeneous cell population (including tumor stem cells), extensive proliferation and migration. Nevertheless, gliomas can also give rise to slow growing tumors and in both cases, the afflux of blood, via BBB is crucial. Glioma cells migrate to different regions of the brain guided by the extension of blood vessels, colonizing the healthy adjacent tissue. In the clinical context, GBM can lead to tumor-derived seizures, which represent a challenge to patients and clinicians, since drugs used for its treatment must be able to cross the BBB. Uncontrolled and fast growth also leads to the disruption of the chimeric and fragile vessels in the tumor mass resulting in peritumoral edema. Although hormonal therapy is currently used to control the edema, it is not always efficient. In this review we comment the points cited above, considering the importance of the blood brain barrier and the concerns that arise when this barrier is affected.

11 June 2019 in Critical Care
Verified
Journal Article
Open access
PDF file
CRCássia Righy
Cássia Righy
RRRegis Goulart Rosa
Regis Goulart Rosa
RSRodrigo Teixeira Amancio da Silva
Rodrigo Teixeira Amancio da Silva
RKRenata Kochhann
Renata Kochhann
CMCelina Borges Migliavaca
Celina Borges Migliavaca
MFMaicon Falavigna
Maicon Falavigna
As more patients are surviving intensive care, mental health concerns in survivors have become a research priority. Among these, post-traumatic stress disorder (PTSD) can have an important impact on the quality of life of critical care survivors. However, data on its burden are conflicting. Therefore, this systematic review and meta-analysis aimed to evaluate the prevalence of PTSD symptoms in adult critical care patients after intensive care unit (ICU) discharge. We searched MEDLINE, EMBASE, LILACS, Web of Science, PsycNET, and Scopus databases from inception to September 2018. We included observational studies assessing the prevalence of PTSD symptoms in adult critical care survivors. Two reviewers independently screened studies and extracted data. Studies were meta-analyzed using a random-effects model to estimate PTSD symptom prevalence at different time points, also estimating confidence and prediction intervals. Subgroup and meta-regression analyses were performed to explore heterogeneity. Risk of bias was assessed using the Joanna Briggs Institute tool and the GRADE approach. Of 13,267 studies retrieved, 48 were included in this review. Overall prevalence of PTSD symptoms was 19.83% (95% confidence interval [CI], 16.72–23.13; I2 = 90%, low quality of evidence). Prevalence varied widely across studies, with a wide range of expected prevalence (from 3.70 to 43.73% in 95% of settings). Point prevalence estimates were 15.93% (95% CI, 11.15–21.35; I2 = 90%; 17 studies), 16.80% (95% CI, 13.74–20.09; I2 = 66%; 13 studies), 18.96% (95% CI, 14.28–24.12; I2 = 92%; 13 studies), and 20.21% (95% CI, 13.79–27.44; I2 = 58%; 7 studies) at 3, 6, 12, and > 12 months after discharge, respectively. PTSD symptoms may affect 1 in every 5 adult critical care survivors, with a high expected prevalence 12 months after discharge. ICU survivors should be screened for PTSD symptoms and cared for accordingly, given the potential negative impact of PTSD on quality of life. In addition, action should be taken to further explore the causal relationship between ICU stay and PTSD, as well as to propose early measures to prevent PTSD in this population. PROSPERO, CRD42017075124 , Registered 6 December 2017.

8 April 2016 in Current Neuropharmacology
Verified
Journal Article
Open access
CRCássia Righy
Cássia Righy
MBMarcelo T. Bozza
Marcelo T. Bozza
MOMarcus F. Oliveira
Marcus F. Oliveira
FBFernando Bozza
Fernando Bozza
Hemorrhagic stroke is a disease with high incidence and mortality rates. In addition to the mass lesions that result from hemorrhagic stroke, substances such as the blood-derived products (BDP) (hemoglobin (Hb), heme and iron) induce a potent inflammatory response and exert direct toxic effects on neurons, astrocytes, and microglia. In the present review, we discuss the mechanisms of brain injury secondary to hemorrhagic stroke, focusing on the involvement of BDP as major players of cellular redox imbalance, inflammation, and glutamate excitotoxicity. Potential natural mechanisms of protection against free Hb and heme such as haptoglobin and hemopexin, respectively, are highlighted. We finally discuss the experimental and clinical trials targeting free iron and heme scavenging as well as inflammation, as potential new therapies to minimize the devastating effects of hemorrhagic stroke on brain structure and function.

1 January 2017 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
CRCássia Righy
Cássia Righy
PBPedro Emmanuel Alvarenga Americano do Brasil
Pedro Emmanuel Alvarenga Americano do Brasil
JVJordi Vallés
Jordi Vallés
FBFernando Bozza
Fernando Bozza
Ignacio Martin-LoechesIgnacio Martin-Loeches
Ignacio Martin-Loeches
Early-onset ventilator-associated pneumonia (EO-VAP) is the leading cause of morbidity and mortality in comatose patients. However, VAP prevention bundles focus mainly on late-onset VAP and may be less effective in preventing EO-VAP in comatose patients. Systemic antibiotic administration at the time of intubation may have a role in preventing EO-VAP. Therefore, we evaluated the effectiveness of systemic antibiotic administration in VAP prevention in comatose patients through a systematic review and meta-analysis. We searched for studies published through December 2015 that evaluated systemic antibiotic prophylaxis in comatose patients. Two authors independently selected and evaluated full-length reports of randomized clinical trials or prospective cohorts in patients aged >16 years that evaluated the impact of systemic antibiotics at the time of intubation on EO-VAP compared to placebo or no prophylaxis. The outcome variables were the incidence of EO-VAP, the duration of mechanical ventilation, ICU length of stay, and ICU mortality. We identified 10,988 citations, yielding 26 articles for further analysis; three studies with 267 patients were finally analyzed. Most patients (n = 135) were comatose due to head trauma. Systemic antibiotic administration was associated with decreased incidence of EO-VAP (RR 0.32; 95% CI 0.19–0.54) and shorter ICU LOS (standardized mean difference −0.32; 95% CI −0.56 to −0.08), but had no effect on mortality (RR 1.03; 95% CI 0.7–1.53) or duration of mechanical ventilation (standardized mean difference −0.16; 95% CI −0.41 to 0.08). Antibiotic prophylaxis in comatose patients reduced the incidence of EO-VAP and decreased the ICU stay slightly. Future trials are needed to confirm these results.

1 September 2010 in Journal of Critical Care
Verified
Journal Article
Closed access
JSJorge I. F. Salluh
Jorge I. F. Salluh
CSCássia Righy Shinotsuka
Cássia Righy Shinotsuka
MSMarcio Soares
Marcio Soares
FBFernando Bozza
Fernando Bozza
JSJOSE R. LAPA E SILVA
JOSE R. LAPA E SILVA
CGCarolina Garcia-Vidal
Carolina Garcia-Vidal

22 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IAIsabel C. T. Almeida
Isabel C. T. Almeida
MSMarcio Soares
Marcio Soares
FBFernando Bozza
Fernando Bozza
CSCassia Righy Shinotsuka
Cassia Righy Shinotsuka
RBRenata Bujokas
Renata Bujokas
JSJorge I. F. Salluh
Jorge I. F. Salluh
Delirium and coma are a frequent source of morbidity for ICU patients. Several factors are associated with the prognosis of mechanically ventilated (MV) cancer patients, but no studies evaluated delirium and coma (acute brain dysfunction). The present study evaluated the frequency and impact of acute brain dysfunction on mortality. The study was performed at National Cancer Institute, Rio de Janeiro, Brazil. We prospectively enrolled patients ventilated >48 h with a diagnosis of cancer. Acute brain dysfunction was assessed during the first 14 days of ICU using RASS/CAM-ICU. Patients were followed until hospital discharge. Univariate and multivariable analysis were performed to evaluate factors associated with hospital mortality. 170 patients were included. 73% had solid tumors, age 65 [53–72 (median, IQR 25%–75%)] years. SAPS II score was 54[46–63] points and SOFA score was (7 [6]–[9]) points. Median duration of MV was 13 (6–21) days and ICU stay was 14 (7.5–22) days. ICU mortality was 54% and hospital mortality was 66%. Acute brain dysfunction was diagnosed in 161 patients (95%). Survivors had more delirium/coma-free days [4(1,5–6) vs 1(0–2), p<0.001]. In multivariable analysis the number of days of delirium/coma-free days were associated with better outcomes as they were independent predictors of lower hospital mortality [0.771 (0.681 to 0.873), p<0.001]. Acute brain dysfunction in MV cancer patients is frequent and independently associated with increased hospital mortality. Future studies should investigate means of preventing or mitigating acute brain dysfunction as they may have a significant impact on clinical outcomes.